Adjuvant Development Program

NIAID/DAIT佐剂开发计划支持开发新的候选疫苗佐剂，其刺激先天免疫应答以保护免受NIAID A、B和C类病原体感染。目前，氢氧化铝/磷酸铝（明矾）是美国唯一许可的一般人类使用的佐剂。因为明矾不是普遍有效的佐剂，所以寻求可以刺激对多种微生物的更广泛有效和安全的应答的另外的佐剂。有资格获得支持的候选疫苗佐剂必须：1）之前已确定并表征为安全，2）通过激活先天免疫系统发挥作用，3）具有记录的佐剂作用机制，4）是产品开发计划的一部分，该计划将在5年合同履行期内显著推进产品，以及5）可能时，在体内动物模型中，在病原性攻击后，能够安全地增强疫苗针对NIAID A、B和C类病原体的效力。

The NIAID/DAIT Adjuvant Development Program supports the development of new candidate vaccine adjuvants that stimulate innate immune responses to protect against infection by NIAID Category A, B, and C Pathogens. Currently, aluminum hydroxide/aluminum phosphate (alum) is the only licensed adjuvant for general human use in the United States. Because alum is not a universally effective adjuvant, additional adjuvants are sought that can stimulate more broadly effective and safe responses to a wide variety of microorganisms. Candidate vaccine adjuvants eligible for support must: 1) be previously identified and characterized as safe, 2) function by activating the innate immune system, 3) have a documented mechanism of action for the adjuvant, 4) be part of a Product Development Plan that will significantly advance the product within the 5 year period of contract performance, and 5) when possible, be able to augment vaccine efficacy safely against an NIAID Category A, B, and C Pathogen upon pathogenic challenge in an in vivo animal model.